Zydus Lifesciences Limited - Asset Resilience Ratio
Zydus Lifesciences Limited (ZYDUSLIFE) has an Asset Resilience Ratio of 9.14% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check ZYDUSLIFE capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Zydus Lifesciences Limited's Asset Resilience Ratio has changed over time. See Zydus Lifesciences Limited net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Zydus Lifesciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Zydus Lifesciences Limited stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0% |
| Short-term Investments | Rs42.86 Billion | 9.14% |
| Total Liquid Assets | Rs42.86 Billion | 9.14% |
Asset Resilience Insights
- Limited Liquidity: Zydus Lifesciences Limited maintains only 9.14% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zydus Lifesciences Limited Industry Peers by Asset Resilience Ratio
Compare Zydus Lifesciences Limited's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA |
Drug Manufacturers - Specialty & Generic | 1.28% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026 |
Drug Manufacturers - Specialty & Generic | -0.89% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Procter & Gamble Health Limited
NSE:PGHL |
Drug Manufacturers - Specialty & Generic | 33.01% |
Annual Asset Resilience Ratio for Zydus Lifesciences Limited (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Zydus Lifesciences Limited.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 18.82% | Rs70.01 Billion ≈ $757.17 Million |
Rs372.02 Billion ≈ $4.02 Billion |
+15.52pp |
| 2024-03-31 | 3.30% | Rs9.67 Billion ≈ $104.54 Million |
Rs292.81 Billion ≈ $3.17 Billion |
+0.58pp |
| 2023-03-31 | 2.72% | Rs7.00 Billion ≈ $75.68 Million |
Rs257.56 Billion ≈ $2.79 Billion |
-7.53pp |
| 2022-03-31 | 10.24% | Rs28.47 Billion ≈ $307.89 Million |
Rs277.95 Billion ≈ $3.01 Billion |
+8.31pp |
| 2021-03-31 | 1.93% | Rs4.62 Billion ≈ $49.96 Million |
Rs238.85 Billion ≈ $2.58 Billion |
-0.15pp |
| 2020-03-31 | 2.09% | Rs4.94 Billion ≈ $53.46 Million |
Rs236.87 Billion ≈ $2.56 Billion |
-0.38pp |
| 2019-03-31 | 2.47% | Rs5.80 Billion ≈ $62.69 Million |
Rs234.83 Billion ≈ $2.54 Billion |
-0.17pp |
| 2018-03-31 | 2.64% | Rs4.77 Billion ≈ $51.61 Million |
Rs180.65 Billion ≈ $1.95 Billion |
+2.24pp |
| 2017-03-31 | 0.40% | Rs614.00 Million ≈ $6.64 Million |
Rs152.21 Billion ≈ $1.65 Billion |
-1.92pp |
| 2016-03-31 | 2.33% | Rs2.33 Billion ≈ $25.21 Million |
Rs100.16 Billion ≈ $1.08 Billion |
+0.99pp |
| 2015-03-31 | 1.34% | Rs1.21 Billion ≈ $13.11 Million |
Rs90.47 Billion ≈ $978.41 Million |
+0.53pp |
| 2014-03-31 | 0.81% | Rs644.00 Million ≈ $6.96 Million |
Rs79.86 Billion ≈ $863.71 Million |
-0.46pp |
| 2013-03-31 | 1.27% | Rs933.00 Million ≈ $10.09 Million |
Rs73.72 Billion ≈ $797.28 Million |
+1.22pp |
| 2012-03-31 | 0.05% | Rs30.00 Million ≈ $324.44K |
Rs63.79 Billion ≈ $689.89 Million |
-- |
About Zydus Lifesciences Limited
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, con… Read more